Associate Professor Claire von Mollendorf of MCRI argues that the lack of progress in measles control over the last two decades suggests that the current strategies are no longer sufficient. She warned that without new and innovative approaches to managing the crisis, the global health situation is likely to deteriorate further. Among the solutions she proposes is the implementation of rapid diagnostic testing, which would allow for better surveillance and earlier detection of outbreaks. This would enable public health officials to respond more quickly and precisely to local surges.
Additionally, Associate Professor von Mollendorf called for new randomized control trials to specifically evaluate the effectiveness of an earlier dosing schedule. Such trials would provide the hard evidence needed to determine if the benefits of early protection outweigh the risks of potentially reduced long-term efficacy. These studies are essential for protecting the millions of babies who are currently left in the "immunity gap," inadequately protected by their mothers’ antibodies and ineligible for the vaccine.
While the global debate continues, some regions are already taking proactive steps based on the emerging data. New Zealand, for instance, has recently updated its recommendations to allow for an additional measles dose to be given to children as young as four months of age if they are traveling to countries where the disease is endemic. This policy shift reflects a growing recognition that the risk of exposure in high-outbreak areas outweighs the traditional concerns regarding the timing of the first dose.
The MCRI review serves as a wake-up call for the international health community. It highlights a critical flaw in the current defense against measles: a biological mismatch between when an infant’s natural protection ends and when their medical protection begins. As the global case count continues to climb in 2025, the pressure to reform vaccination schedules is mounting. The challenge for the WHO and national health departments will be to balance the immediate need to protect vulnerable infants with the long-term logistical and immunological goals of measles elimination. In a world where a highly contagious virus can cross borders with ease, the window for closing the immunity gap is narrowing, and the cost of inaction continues to rise.
